Mallinckrodt plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven J. Romano
- Full Time Employees
- 2,778
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- College Business & Technology Park Dublin Ireland 15
- CIK
- 0001567892
- Website
- mallinckrodt.com
- Similar Companies
- Business
- Mallinckrodt plc Mallinckrodt plc is a global specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic therapeutics addressing complex medical conditions. Founded in 1867 and headquartered in Dublin, Ireland, with operational headquarters in the United States and executive offices in Staines-upon-Thames, England, the company operates primarily in the U.S., Europe, Middle East, Africa and other international markets. Its core businesses encompass two main segments: Specialty Brands, featuring branded pharmaceuticals for autoimmune and rare diseases in areas including neurology, rheumatology, nephrology, pulmonology, ophthalmology, oncology, immunotherapy, neonatal respiratory critical care, analgesics, cultured skin substitutes and gastrointestinal products such as Acthar Gel (corticotropin for inflammatory and autoimmune conditions), Terlivaz, Ofirmev (acetaminophen injection) and other therapies in endocrinology, gastroenterology and hepatology; and Specialty Generics, offering a broad portfolio of generic prescription drugs, active pharmaceutical ingredients (APIs), sterile injectables, hydrocodone- and oxycodone-containing tablets, other controlled substances for pain management, medications for attention-deficit/hyperactivity disorder and addiction treatment including buprenorphine/naloxone equivalents, codeine, dextroamphetamine, fentanyl citrate, hydromorphone and more, supported by robust U.S.-advantaged manufacturing capabilities. In a transformative series of recent developments, Mallinckrodt plc completed a $6.7 billion merger with Endo International in August 2025, creating a diversified therapeutics leader with complementary portfolios in branded specialties and generics; subsequently spun off its generics, sterile injectables and API business as the independent Par Health company in November 2025; and rebranded its remaining branded therapeutics operations as Keenova Therapeutics, which focuses on advancing therapies for unmet needs in immunology, urology, hepatology, ophthalmology, orthopedics, critical care and related areas including XIAFLEX for Dupuytren's contracture and Peyronie's disease, with plans to pursue a public equity listing in 2026. Prior to these changes, the company sold its Therakos immunotherapy business to CVC Capital Partners for $925 million in 2024. Keenova Therapeutics, as the evolved entity from Mallinckrodt's branded portfolio, maintains a strong balance sheet for pipeline growth, business development and value creation across its targeted therapeutic franchises.
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million
Mallinckrodt to Report Earnings Results for Second Quarter 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors with Over $1 Million in Losses to Secure Counsel Before Important Deadline in Securities Class Action – MNK, MNKPF
Levi Strauss shares tumble on outlook cut, Mallinckrodt and Alibaba shares rise and more stocks on the move
Why is Mallinckrodt (MNK) Stock Down 27% Today?
Mallinckrodt to Report Earnings Results for Third Quarter 2022
Silence Therapeutics receives further US$2mln under Mallinckrodt deal
Silence Therapeutics receives further US$2mln under Mallinckrodt deal
Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment